A phase III randomized controlled study on the efficacy and improved bowel function of prolonged‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

BACKGROUND: Oxycodone/naloxone (OXN PR) is a prolonged‐release formulation containing oxycodone and naloxone in a 2:1 ratio. This study aimed to evaluate the tolerability and efficacy of doses up to OXN160/80 mg PR compared with oxycodone prolonged‐release formulation (OxyPR) in a randomised control...

Descripción completa

Detalles Bibliográficos
Autores principales: Dupoiron, D., Stachowiak, A., Loewenstein, O., Ellery, A., Kremers, W., Bosse, B., Hopp, M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600007/
https://www.ncbi.nlm.nih.gov/pubmed/28641363
http://dx.doi.org/10.1002/ejp.1054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5600007/
https://www.ncbi.nlm.nih.gov/pubmed/28641363
http://dx.doi.org/10.1002/ejp.1054

Ejemplares similares